{"id":"NCT00753896","sponsor":"AstraZeneca","briefTitle":"Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin","officialTitle":"Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-10","primaryCompletion":"2009-07","completion":"2009-11","firstPosted":"2008-09-17","resultsPosted":"2012-03-20","lastUpdate":"2015-04-21"},"enrollment":134,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes"],"interventions":[{"type":"DRUG","name":"exenatide","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"}],"summary":"This study will examine the safety of exenatide once weekly (2.0 mg) in approximately 134 patients receiving treatment with thiazolidinedione alone or thiazolidinedione in combination with metformin. Patients are expected to be treated with exenatide once weekly for at least 52 weeks.","primaryOutcome":{"measure":"Percentage of Patients Experiencing Adverse Events","timeFrame":"Baseline to Week 52","effectByArm":[{"arm":"Exenatide Once Weekly","deltaMin":73.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":20},"locations":{"siteCount":26,"countries":["United States","Canada","Mexico","Romania","South Africa"]},"refs":{"pmids":["23031623"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":134},"commonTop":["Nausea","Injection site nodule","Nasopharyngitis","Decreased appetite","Headache"]}}